CLDI

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split"). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of "CLDI." The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 507. The decision to implement this stock split reflects the Company’s ai

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment ("TME"). The poster is available here. "The data presented at today’s summit shows the advances we have made with the RedTail platform and our progress in addressing a central challenge in immuno-oncology: how to deliver tumor-speci

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received pre-IND regulatory feedback from the U.S. Food and Drug Administration (FDA) providing alignment and clarity on Calidi's IND-enabling preclinical plans and clinical strategy for CLD-401 prior to advancing the drug candidate into Phase 1 clinical studies. "We thank the FDA for its regulatory feedback, and we believe we are in agreement with the agency on our overall IND strategy for CLD-401," said Calidi Biotherapeutics Chief Executive Officer Eric Poma, Ph.D.

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, will participate in an investor webinar hosted by RedChip Companies ("RedChip") on June 9, 2026, at 1:15pm PT. The exclusive event will feature Eric Poma, Ph.D., Chief Executive Officer of Calidi, who will provide investors with an in-depth overview of Calidi's breakthrough RedTail platform, a next-generation targeted virotherapy designed to deliver genetic medicines systemically to metastatic sites of disease. The discussion will highlight the Company's progress advancing CLD-401, its lead RedT

DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that two abstracts showcasing the Company's RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 29 to June 2, 2026 in Chicago, IL. The Company's proprietary RedTail platform is a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors. The

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today advised that its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming that the Company will continue as a going concern. Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment

SCHEDULE 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo T-cell engagers that simultaneously express both a T-cell engager and a T-cell activator at high levels exclusively in the tumor microenvironment; presented new data on CLD-501, a TROP-2 in vivo T-cell engagerDemonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026Speaker presentation at ASGCT conference in Boston, MA highl

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, will speak tomorrow at the annual conference of the American Society for Gene and Cell Therapy (ASGCT) in Boston, Massachusetts. Dr. Santidrian was invited to speak at the conference and detail the exciting promise of Calidi's RedTail platform and pipeline. The Company's proprietary RedTail platform is a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor mic

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

DEF 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced today that it has entered into a collaboration with TransferAI to drive efficiencies in its IND submission for CLD-401 by using TransferAI's proprietary agentic artificial intelligence platform, SofieTM, including pre-built and customizable orchestrations for biopharma. CLD-401 is the lead candidate from the Company's RedTail platform, a systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expressi

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 21 2026. The Company showcased new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist ("IL-15 SA") only in the tumor microenvironment ("TME"), currently in IND-enabling studies. The poster is available here. CLD-401 is the lead candidate from the Company's Red

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment ("TME"). The poster is available here. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level